Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| EAR | Lowlands Results Point to Open Pit Potential | PRICE SENSITIVE | 24/04/18 | |
| EAR | Quarterly Activities and Cashflow Report | PRICE SENSITIVE | 23/04/18 | |
| EAR | Orelia Deep Drilling Results | PRICE SENSITIVE | 13/04/18 | |
| EAR | Clarification of Map | 23/03/18 | ||
| EAR | Half Year Accounts | 16/03/18 | ||
| EAR | Initial Director's Interest Notice (GL) | 14/03/18 | ||
| EAR | Appointment of Finance Director | 08/03/18 | ||
| EAR | New Gold Province | PRICE SENSITIVE | 07/03/18 | |
| EAR | Change in substantial holding | 02/02/18 | ||
| EAR | Orelia Delivers Strike Extensions | PRICE SENSITIVE | 24/01/18 | |
| EAR Lowlands Results Point to Open Pit Potential | |||
| 24/04/18 | PRICE SENSITIVE | ||
| EAR Quarterly Activities and Cashflow Report | |||
| 23/04/18 | PRICE SENSITIVE | ||
| EAR Orelia Deep Drilling Results | |||
| 13/04/18 | PRICE SENSITIVE | ||
| EAR Clarification of Map | |||
| 23/03/18 | |||
| EAR Half Year Accounts | |||
| 16/03/18 | |||
| EAR Initial Director's Interest Notice (GL) | |||
| 14/03/18 | |||
| EAR Appointment of Finance Director | |||
| 08/03/18 | |||
| EAR New Gold Province | |||
| 07/03/18 | PRICE SENSITIVE | ||
| EAR Change in substantial holding | |||
| 02/02/18 | |||
| EAR Orelia Delivers Strike Extensions | |||
| 24/01/18 | PRICE SENSITIVE | ||
